Jump to main content
Jump to site search

Issue 12, 2014
Previous Article Next Article

3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors

Author affiliations

Abstract

The chromatin remodeling amine oxidase lysine-specific demethylase 1 (LSD1) has become an attractive target for the design of specific inhibitors with therapeutic potential. We, and others, have described LSD1 inhibitors that have potential as antitumor agents. Many of the currently known LSD1 inhibitors are poor drug candidates, or are structurally based on the tranylcypromine backbone, thus increasing the potential for off-target effects mediated by other amine oxidases. We now describe a series of potent LSD1 inhibitors based on a novel 1,2,4-triazole scaffold; these inhibitors show a high degree of specificity for LSD1 in vitro, and cause increases in cellular histone 3 dimethyllysine 4 (H3K4me2), a gene transcription activating mark. Importantly, these inhibitors exhibit low toxicity towards mammalian cells in vitro, and thus they may show utility in the treatment of epigenetically-based diseases where cell death is not a desired endpoint.

Graphical abstract: 3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors

Back to tab navigation

Supplementary files

Publication details

The article was received on 29 Jun 2014, accepted on 21 Aug 2014 and first published on 22 Aug 2014


Article type: Concise Article
DOI: 10.1039/C4MD00283K
Author version
available:
Download author version (PDF)
Citation: Med. Chem. Commun., 2014,5, 1863-1870
  •   Request permissions

    3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors

    C. J. Kutz, S. L. Holshouser, E. A. Marrow and P. M. Woster, Med. Chem. Commun., 2014, 5, 1863
    DOI: 10.1039/C4MD00283K

Search articles by author

Spotlight

Advertisements